Current Trends in Pediatric Migraine: Clinical Insights and Therapeutic Strategies DOI Creative Commons
Adnan Khan, Sufang Liu, Feng Tao

и другие.

Brain Sciences, Год журнала: 2025, Номер 15(3), С. 280 - 280

Опубликована: Март 6, 2025

Background/Objectives: Pediatric migraine is a prevalent neurological disorder that significantly impacts children’s quality of life, academic performance, and social interactions. Unlike migraines in adults, pediatric often present differently involve unique underlying mechanisms, making diagnosis treatment more complex. Methods: This review discusses the clinical phases migraine, key trigger factors, sex- age-related differences, role childhood maltreatment development. We also discuss episodic syndromes such as cyclic vomiting syndrome, abdominal benign paroxysmal vertigo, torticollis, along with comorbidities psychiatric disorders, sleep disturbances, epilepsy. Results: The pathophysiological mechanisms for migraines, including genetic predispositions, neuroinflammation, gut microbiota dysbiosis, are summarized. Current therapeutic strategies, conventional emerging pharmacological treatments, nutraceuticals, non-pharmacological approaches, evaluated. Non-pharmacological particularly evidence-based lifestyle interventions stress management, diet, hydration, sleep, exercise, screen time moderation, cognitive behavioral therapy, highlighted components prevention management. long-term prognosis follow-up patients reviewed, emphasizing importance early diagnosis, tailored multidisciplinary care to prevent chronic progression. Conclusions: Future research should focus on novel targets integrating gut–brain axis modulation, need longitudinal studies better understand course migraine.

Язык: Английский

A comprehensive review on pharmacological applications and drug-induced toxicity of valproic acid DOI Creative Commons
Ayesha Safdar, Fátima Ismail

Saudi Pharmaceutical Journal, Год журнала: 2022, Номер 31(2), С. 265 - 278

Опубликована: Дек. 9, 2022

Valproic acid, a branching short chain fatty is popular drug to treat epilepsy and acts as mood-stabilizing drug. The obstruction of ion channels Gamma Amino Butyrate transamino butyrate GABA has been linked antiepileptic effects. acid characterized Histone deacetylase inhibitor, functioning directly transcription gene levels by blocking the deacetylation histones increasing accessibility sites. Study extensively focused on pharmaceutical activity valproic through various pharmacodynamics from absorption, distribution excretion particularly in patients who are resistant or intolerant lithium carbamazepine, well those with mixed mania rapid cycling.

Язык: Английский

Процитировано

42
Gepants for Acute and Preventive Migraine Treatment: A Narrative Review DOI Creative Commons
Jamir Pitton Rissardo, Ana Letícia Fornari Caprara

Brain Sciences, Год журнала: 2022, Номер 12(12), С. 1612 - 1612

Опубликована: Ноя. 24, 2022

Calcitonin gene-related peptide (CGRP) antagonists are a class of medications that act as the CGRP receptor or ligand. They can be divided into monoclonal antibodies and non-peptide small molecules, also known gepants. were first oral agents specifically designed to prevent migraines. The second generation gepants includes rimegepant (BHV-3000, BMS-927711), ubrogepant (MK-1602), atogepant (AGN-241689, MK-8031). Zavegepant (BHV-3500, BMS-742413) belongs third characterized by different administration routes. chemical pharmacological properties this new calculated. clinical trials showed is effective for acute and/or preventive treatment No increased mortality risks observed associated with second- third-generation Moreover, majority serious adverse events reported probably occurred unrelated medications. Interesting facts about highlighted, such potency, hepatotoxicity, concomitant use targeting CGRP, comparative analysis triptans, “acute preventive” migraine. Further studies should include an elderly population compare inside triptans. There still concerns regarding long-term side effects these medications, chronic vascular hemodynamic impairment. Meanwhile, careful pharmacovigilance safety monitoring performed in practice

Язык: Английский

Процитировано

40
Rebalancing NOX2/Nrf2 to limit inflammation and oxidative stress across gut-brain axis in migraine DOI Creative Commons
Alessio Ardizzone, Anna Paola Capra,

Alberto Repici

и другие.

Free Radical Biology and Medicine, Год журнала: 2024, Номер 213, С. 65 - 78

Опубликована: Янв. 20, 2024

Язык: Английский

Процитировано

15
Genetics of migraine: complexity, implications, and potential clinical applications DOI
Heidi G. Sutherland, Bronwyn Jenkins, Lyn R. Griffiths

и другие.

The Lancet Neurology, Год журнала: 2024, Номер 23(4), С. 429 - 446

Опубликована: Март 18, 2024

Язык: Английский

Процитировано

14
Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products DOI Open Access

Yalan Zhou,

Siqi Peng, Huizhen Wang

и другие.

Genes, Год журнала: 2024, Номер 15(4), С. 468 - 468

Опубликована: Апрель 8, 2024

In recent years, the FDA has approved numerous anti-cancer drugs that are mutation-based for clinical use. These have improved precision of treatment and reduced adverse effects side effects. Personalized therapy is a prominent hot topic current medicine also represents future direction development. With continuous advancements in gene sequencing high-throughput screening, research development strategies personalized developed rapidly. This review elaborates strategies, which include artificial intelligence, multi-omics analysis, chemical proteomics, computation-aided drug design. technologies rely on molecular classification diseases, global signaling network within organisms, new models all targets, significantly support medicine. Meanwhile, we summarize drugs, such as lorlatinib, osimertinib, other natural products, deliver therapeutic based genetic mutations. highlights potential challenges interpreting mutations combining while providing ideas pharmacogenomics cancer study.

Язык: Английский

Процитировано

14
Untangling the mess of CGRP levels as a migraine biomarker: an in-depth literature review and analysis of our experimental experience DOI Creative Commons
Gabriel Gárate, Julio Pascual,

Marta Pascual-Mato

и другие.

The Journal of Headache and Pain, Год журнала: 2024, Номер 25(1)

Опубликована: Апрель 29, 2024

Abstract Background Calcitonin gene-related peptide (CGRP) is the most promising candidate to become first migraine biomarker. However, literature shows clashing results and suggests a methodological source for such discrepancies. We aimed investigate some of these factors evaluate actual role CGRP as Methods Previous experimental part, we performed review articles measuring in patients. Using our 399 bio-bank sera samples, series experiments test validity different ELISA kits employed, time sample processing, long-term storage, sampling rest or after moderate exercise. Analysis in-house data was analyse average levels effect sex age. Results Literature high variability terms study design, determination methods, conclusions obtained by studies including determinations measurements depends on method specific kit also isoform detected, showing completely ranges concentrations. Alpha-CGRP beta-CGRP had median with IQR 37.5 (28.2–54.4) 4.6 (2.4–6.4)pg/mL, respectively. content preserved serum within 24 hours when samples are stored at 4°C clotting immediate centrifugation. Storages -80°C more than 6 months result decrease levels. Moderate exercise prior blood extraction does not modulate concentration peptide. Age positively correlates men have higher alpha-CGRP women. Conclusions present valuable information serum. suitability should be tested experiments. Alpha analysed separately they can show behaviours even same condition. Samples processed 24-h window if been kept before assayed. Patients do need unless high-endurance For comparative studies, age accounted parameters impact Graphical

Язык: Английский

Процитировано

14
Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics DOI Creative Commons

Kofi Frimpong-Manson,

Yuma T. Ortiz, Lance Richard McMahon

и другие.

Frontiers in Molecular Neuroscience, Год журнала: 2024, Номер 17

Опубликована: Фев. 28, 2024

The individual and global burden of migraine is such significance that there are accelerated efforts to develop new therapies. New therapeutics needed address the current deficiencies exist in efficacy adherence rate approved anti-migraine medications. recent discovery calcitonin gene related peptide as an add-on role serotonin has markedly increased range treatment options for acute chronic migraine. Despite this, tackling complexity disorders requires a complete understanding its pathophysiology. Preclinical animal models can shed light on disease-related pathophysiology, including Indeed, use been instrumental developing many therapeutics. However, model limited by predictive face validity model, this extends preclinical models. In review, summary pathophysiology given from both clinical perspective, emphasis placed We will discuss strengths pitfalls common well experimental research areas explore further.

Язык: Английский

Процитировано

9
Identifying therapeutic target genes for migraine by systematic druggable genome-wide Mendelian randomization DOI Creative Commons
Chengcheng Zhang,

Yiwei He,

Lu Liu

и другие.

The Journal of Headache and Pain, Год журнала: 2024, Номер 25(1)

Опубликована: Июнь 12, 2024

Currently, the treatment and prevention of migraine remain highly challenging. Mendelian randomization (MR) has been widely used to explore novel therapeutic targets. Therefore, we performed a systematic druggable genome-wide MR potential targets for migraine.

Язык: Английский

Процитировано

9
Galectin‐1 Regulates Inflammatory Responses and Promotes Microglial M2 Polarization in Chronic Migraine DOI Open Access
Yue Xiao, Wei Han, Ming Yu

и другие.

European Journal of Neuroscience, Год журнала: 2025, Номер 61(3)

Опубликована: Фев. 1, 2025

Chronic migraine (CM) is a severe and debilitating neurological disorder with an unclear pathophysiology. Galectin-1, β-galactoside-binding protein, known for its anti-inflammatory immune-regulatory effects in various inflammation-related diseases. However, role CM has not been fully elucidated. In this study, we analysed data from patients employed nitroglycerin-induced mouse model to explore the potential of galectin-1. Serum galectin-1 levels were significantly lower compared healthy controls. Additionally, negatively correlated Visual Analogue Scale (VAS) Headache Impact Test (HIT-6) scores. also exhibited elevated IL-6 TNF-α reduced IL-10. Notably, inversely positively model, expression was spinal trigeminal nucleus caudalis (Sp5C) region. Supplementation increased paw periorbital mechanical thresholds light aversion anxiety-like behaviours. Moreover, enhanced microglial morphology, promoted M2 polarization, pro-inflammatory factors cytokine Mechanistically, on microglia may involve activation PI3K/AKT signalling pathway, as evidenced by phosphorylation PI3K AKT. summary, our study demonstrates that plays crucial pathogenesis chronic migraine. Exogenous supplementation effectively alleviates symptoms promotes suggesting represent novel therapeutic target CM.

Язык: Английский

Процитировано

1
Epigenetic Connection of the Calcitonin Gene-Related Peptide and Its Potential in Migraine DOI Open Access
Michał Fila, Anna Sobczuk, Elżbieta Pawłowska

и другие.

International Journal of Molecular Sciences, Год журнала: 2022, Номер 23(11), С. 6151 - 6151

Опубликована: Май 30, 2022

The calcitonin gene-related peptide (CGRP) is implicated in the pathogenesis of several pain-related syndromes, including migraine. Targeting CGRP and its receptor by their antagonists antibodies was a breakthrough migraine therapy, but need to improve efficacy limit side effects these drugs justify further studies on regulation expression encoding gene, CALCA, modulated epigenetic modifications, DNA methylation, histone modification, micro RNAs (miRNAs), circular RNAs, long-coding (lncRNAs). On other hand, can change profile neuronal glial cells. promoter CALCA gene has two CpG islands that may be specifically methylated patients. methylation lncRNAs were shown play role cell-specific alternative splicing primary transcript. involved changes neural cytoarchitecture are controlled deacetylase 6 (HDAC6) related Inhibition HDAC6 results reduced cortical-spreading depression blockade receptor. levels associated with miRNAs plasma, making them useful peripheral markers fundamental inflammatory pain transmission epigenetically regulated. In conclusion, connections should explored for efficient safe antimigraine therapy.

Язык: Английский

Процитировано

26